Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsReceivables - AccuredRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Other Non-Current Assets (2016 - 2025)

Spyre Therapeutics (SYRE) has disclosed Other Non-Current Assets for 10 consecutive years, with $10000.0 as the latest value for Q4 2024.

  • For the quarter ending Q4 2024, Other Non-Current Assets rose 11.11% year-over-year to $10000.0, compared with a TTM value of $10000.0 through Dec 2024, up 11.11%, and an annual FY2024 reading of $10000.0, up 11.11% over the prior year.
  • Other Non-Current Assets was $10000.0 for Q4 2024 at Spyre Therapeutics, roughly flat from $10000.0 in the prior quarter.
  • Across five years, Other Non-Current Assets topped out at $1.8 million in Q1 2021 and bottomed at $9000.0 in Q4 2023.
  • Average Other Non-Current Assets over 5 years is $935350.0, with a median of $1.1 million recorded in 2021.
  • The sharpest move saw Other Non-Current Assets tumbled 99.45% in 2023, then surged 3110.0% in 2024.
  • Year by year, Other Non-Current Assets stood at $1.8 million in 2020, then plummeted by 54.29% to $842000.0 in 2021, then skyrocketed by 84.44% to $1.6 million in 2022, then plummeted by 99.42% to $9000.0 in 2023, then increased by 11.11% to $10000.0 in 2024.
  • Business Quant data shows Other Non-Current Assets for SYRE at $10000.0 in Q4 2024, $10000.0 in Q3 2024, and $321000.0 in Q2 2024.